¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Multiple Test Strip Device Misc"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
¿µ¹® Coombs test ÇÑ±Û Å©¿òÁî°Ë»ç
¼³¸í   
  ÀûÇ÷±¸¿¡ ´ëÇÑ Ç×ü¸¦ °Ë»çÇϴ ¹æ¹ý. Ç×ü¶õ Æ¯Á¤ÇÑ ¹°Áú¿¡ ºÎÂøµÇ¾î ±× ¹°ÁúÀÇ ÀÛ¿ëÀ» ¾ïÁ¦Çϰí, ¶Ç´Â ±× ¹°ÁúÀ» ÆÄ±«Çϴ °ÍÀ¸·Î B-¸²ÇÁ±¸¶ó´Â ¸é¿ªÀ» ´ã´çÇϴ ¼¼Æ÷¿¡ ÀÇÇØ¼­ ¸¸µé¾îÁø´Ù. ÀÌ Å©¿òÁî°Ë»ç¿¡´Â Á÷Á¢Å©¿òÁî°Ë»ç¿Í °£Á¢Å©¿òÁî°Ë»çÀÇ µÎ °¡Áö°¡ Àִµ¥ Á÷Á¢ Å©¿òÁî°Ë»ç´Â ¸ö¼ÓÀÇ ÀûÇ÷±¸¿¡ Á÷Á¢ ºÎÂøµÇ¾î Àִ Ç×ü¸¦ °Ë»çÇϴ ¹æ¹ýÀÌ´Ù. Ã¤ÃëÇÑ Ç÷¾×À» ÀûÇ÷±¸¸¦ ¾ò¾î¼­ »ç¶÷ÀÇ Ç×ü¿¡ ´ëÇÑ Ç×ü(»ç¶÷ÀÇ Ç×ü¿¡ Æ¯Á¤ÇϰԠºÎÂøÀÌ µÇ´Â Ç×ü)¸¦ ¹ÝÀÀ½Ã۸é, ¸¸¾à ÀûÇ÷±¸¿¡ ´ëÇÑ Ç×ü°¡ ºÎÂøµÇ¾î Àִ ÀûÇ÷±¸¶ó¸é »ç¶÷ÀÇ Ç×ü¿¡ ´ëÇÑ Ç×ü°¡, ÀÛ¿ëÇÏ¿© Ä§°­ ¹ÝÀÀÀÌ ÀϾ°Ô µÇ°í Ç×ü°¡ ºÎÂøµÇ¾î ÀÖÁö ¾Ê´Â ÀûÇ÷±¸À̸頹ÝÀÀÀÌ ÀϾÁö ¾Ê´Â °ÍÀ» ÀÌ¿ëÇÑ´Ù. °£Á¢Å©¿òÁî°Ë»ç´Â Ç÷Àå¼Ó¿¡ Á¸ÀçÇϴ ÀûÇ÷±¸¿Í ºÎÂøµÇ¾î ÀÖÁö ¾ÊÀº Ç×ü¸¦ Ã£¾Æ³»´Â ½ÃÇèÀ¸·Î Ç÷ÀåÀ» Ã¤ÃëÇØ¼­ ´Ù¸¥ »ç¶÷ÀÇ ÀûÇ÷±¸¿Í ¹ÝÀÀÀ» ½ÃŰ°í ¿ª½Ã Ç×ü¿¡ ´ëÇÑ Ç×ü¸¦ ¹ÝÀÀ½ÃÄѠħ°­¹ÝÀÀÀ» °üÂûÇØ¼­ ±× Ç×ü¸¦ Ã£¾Æ³»´Â ¹æ¹ýÀÌ´Ù.
¿µ¹® tuberculin test ÇÑ±Û Æ©º£¸£Ä𸰰˻ç
¼³¸í   
  ¸¹Àº ¼­·Î ´Ù¸¥ ÇüÅÂÀÇ Æ©º£¸£Ä𸰰ú ´Ù¾çÇÑ Åõ¿©¹æ¹ý¿¡ ÀÇÇÑ ¸ðµç Á¾·ùÀÇ °áÇÙ ÇǺΰ˻ç¹ý. ÇöÀç Ç¥ÁØ ½ÃÇè¹ýÀ¸·Î µÇ¾îÀִ °¡À堽źù¼ºÀִ °Ë»ç·Î´Â PPD¸¦ Çdz»ÁÖ»çÇϴ ¹æ¹ý¸ÁÅä¿ì °Ë»çÀÌ´Ù. Çdz»ÁÖ»çÈÄ 48~72½Ã°£ ÈÄ¿¡ ÁÖ»çºÎÀ§¿¡ Á÷°æ 10mmÀÌ»óÀ¸·Î º¸À̸ç, ¸¸Á®Áö´Â È«¹Ý°ú °æÈ­°¡ ³ªÅ¸³ª¸é ¾ç¼ºÀÌ´Ù. ¼ºÀο¡°Ô´Â ÀϹÝÀûÀ¸·Î Áß°£ °­µµÀÇ Æ©º£¸£Äð¸°(5Tu)À» »ç¿ëÇϸç, ¾ç¼º¹ÝÀÀÀÌ ³ªÅ¸³ª¸é °áÇÙ±Õ¿¡ ÀÌÀü¿¡ °¨¿°µÇ¾ú°Å³ª ÇöÀç °¨¿°µÇ¾î Àִٴ ȮÁ¤Àû Áø´ÜÀÌ µÈ´Ù. À½¼º¹ÝÀÀÀº °áÇÙÀÌ ¾ø°Å³ª, ½ÉÇÑ °áÇÙ°¨¿°¿¡ ÀÇÇÑ ÇǺξ˷¹¸£±â°¡ ÀÖÀ» °æ¿ì, ¶Ç´Â ¸é¿ª¾ïÁ¦¸¦ ³ªÅ¸³»´Â º´, ¿¹¸¦ µé¸é È£ÁöŲº´À̳ª »ç¸£ÄÚÀ̵åÁõ µîÀÌ ÇÕº´µÈ °æ¿ìÀÌ´Ù.
¿µ¹® Papanicolaou smear(test) ÇÑ±Û ÆÄÆÄ´ÏÄÝ·Î µµ¸»°Ë»ç
¼³¸í   
  ÁÙ¿©¼­ ÆËµµ¸»°Ë»ç(Pap smear)À̶ó°í ºÎ¸¥´Ù. ¿©¼ºÀÇ Àڱøñ¾ÏÀÇ ¹ß»ýÀ» ¹Ì¸® ¾Ë¾Æº¸±â À§ÇØ ½ÃÇàÇϴ °Ë»ç¹ýÀ¸·Î ¹Ì±¹¿¡¼­´Â ÀÌ ¹æ¹ýÀ¸·Î ÇöÀç Àڱøñ¾Ï¹ß»ý¿¡ ÀÇÇÑ »ç¸Á·üÀ» ÇöÀúÈ÷ ³·Ãß°í ÀÖ´Ù. ¹æ¹ýÀº »êºÎÀΰú¿¡¼­ ½ÃÇàÇϸç, ¿©¼ºÀÇ Àڱøñ¿¡¼­ ¼¼Æ÷¸¦ °¡Á®´Ù°¡ µµ¸»ÇÏ¿© Çö¹Ì°æÀ¸·Î °Ë»çÇÑ´Ù. ¿äÁîÀ½¿¡ ¿Í¼­´Â Àڱøñ»Ó ¾Æ´Ï¶ó È£Èí±â³ª ºñ´¢±â µî ºÐºñ¹°À» µµ¸»ÇÏ¿© ÆÄÆÄ´ÏÄݷΠ¿°»öÀ» ÇÏ¿© °Ë»çÇϴ °Íµµ ¿©±â¿¡ Æ÷ÇԵȴÙ.
  
  (±×¸² P-3).
¿µ¹® glucose tolerance test ÇÑ±Û Æ÷µµ´ç°ßµõ°Ë»ç
¼³¸í   
  Æ÷µµ´ç°ßµõ °Ë»ç¶õ ´ç´¢º´ÀÇ Áø´Ü¿¡ »ç¿ëµÇ´Â °Ë»ç·Î ´çÀ» Ã¼³»¿¡ Åõ¿©ÇÏ°í ½Ã°£ º°·Î Ç÷¾×À» Ã¤ÃëÇÏ¿© Ç÷´çÀÇ ³óµµ¸¦ Àç¾î¼­ °íÇ÷´ç ¿©ºÎ¸¦ Á¶»çÇϴ °Ë»çÀÌ´Ù. ÁַΠ°æ±¸Æ÷µµ´ç°ßµõ°Ë»ç(oral glucose tolerance test)¸¦ ¸¹ÀÌ Çϴµ¥ À̰ÍÀº 10~16½Ã°£ÀÇ ±Ý½Ä ÈÄ¿¡ Ã¤Ç÷À» Çѹø Çѵڿ¡ µµ´ç 75gÀ» 250~300mLÀÇ ¹°¿¡ ³ì¿© 5ºÐ¿¡ °ÉÃļ­ ¸¶½Ã°Ô ÇÏ°í ¸Å½Ã°£ º°·Î Ã¤Ç÷À» ÇÏ¿© Ç÷´çÀÇ ³óµµ¸¦ Ã½Å©ÇÑ´Ù. °øº¹½Ã¿¡ Á¤¸Æ¿¡¼­ Ã¤Ç÷ÇÏ¿© ÃøÁ¤ÇÑ Ç÷´çÀÌ 140mg/dLÀÌ»óÀ̰ųª Æ÷µµ´ç°ßµõ °Ë»ç 2½Ã°£ÈÄÀÇ Ç÷´çÀÌ 200mg/dLÀÌ»óÀÏ °æ¿ì¿¡´Â ´ç´¢º´À¸·Î Áø´ÜÀ» ÇÑ´Ù. ±×·¯³ª ÀÌ °Ë»ç¸¦ ½Ç½ÃÇÒ °æ¿ì¿¡ ÁÖÀÇÇØ¾ß ÇÒ Á¡Àº °Ë»çÀü 3Àϰ£ ÇÏ·ç¿¡ 150gÀÌ»óÀǠź¼öÈ­¹°À» ¼·ÃëÇØ¾ß ÇѴٴ °Í°ú °Ë»çµµÁß¿¡ ¿îµ¿, Èí¿¬ µîÀ» ÇÏÁö ¾Ê¾Æ¾ß ÇѴٴ °ÍÀÌ´Ù. 
¿µ¹® blood test ÇÑ±Û Ç÷¾×°Ë»ç
¼³¸í   
  Ç÷¾×ÇüÀ̳ª Áúº´ À¯¹« µûÀ§¸¦ ¾Ë±â À§ÇÏ¿© ÇǸ¦ »Ì¾Æ ÇàÇϴ °Ë»ç. ¸ö ÀüüÀÇ Àå±â³ª Á¶Á÷¿¡ º´ÅͰ¡ ÀÖÀ¸¸é À̵頼ººÐ¿¡ º¯È­°¡ ÀÖ°Ô µÇ¾î Áø´Ü¿¡ Å« µµ¿òÀ» ÁØ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • multiple infection
    º¹¼ö°¨¿°, ¿©·¯¹ø°¨¿°
  • multiple intestinal polyposis
    ´Ù¹ßÀåÆú¸³Áõ
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ, ´Ù¹ßÀåÁßøÁõ
  • multiple keratoacanthoma
    ´Ù¹ß°¢Áú°¡½Ã¼¼Æ÷Á¾
  • multiple labor
    ´Ù»ê, ´Ùźи¸
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple myositis
    ´Ù¹ß±Ù(À°)¿°
  • multiple neurofibromatosis
    ´Ù¹ß½Å°æ¼¶À¯Á¾Áõ
  • multiple neuroma
    ´Ù¹ß½Å°æÁ¾
  • multiple paramyoclonus
    ´Ù¹ß±Ù´ë¼º¹ßÀÛ
  • multiple peripheral neuritis
    ´Ù¹ß¸»ÃʽŰ濰
  • multiple personality
    ´ÙÁßÀΰÝ
  • multiple personality disorder
    ´ÙÁßÀΰÝÀå¾Ö
  • multiple pregnancy
    ´ÙÅÂÀÓ½Å, ¹µÀÓ½Å
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´çºÎÇϰ˻ç
  • osmotic fragility test
    »ïÅõ¾ÐÃë¾à¼º°Ë»ç, »ïÅõ¾Ð¿©¸²¼º°Ë»ç
  • Pap test
    (¢¡Papanicolaou test) ÆÄÆÄ´ÏÄݷΰ˻ç
  • Papanicolaou test
    ÆÄÆÄ´ÏÄݷΰ˻ç
  • patch test
    ÇǺÎÁ¢Ã˰˻ç, øÆ÷°Ë»ç
  • paternity test
    Ä£ÀÚ°¨Á¤
  • pilot test
    ¿¹ºñ°Ë»ç
  • pin prick test
    ¹Ù´Ãµû²û°Ë»ç, ¹Ù´ÃÅë°¢°Ë»ç
  • postcoital test
    ¼º±³Èİ˻ç
  • pregnancy test
    ÀӽŰ˻ç
  • provocation test
    À¯¹ß°Ë»ç, À¯¹ß¹ÝÀÀ°Ë»ç
  • pulmonary function test
    Æó±â´É°Ë»ç
  • quantitative test
    Á¤·®°Ë»ç
  • reduction test
    ȯ¿ø½ÃÇè
  • renal function test
    ÄáÆÏ±â´É°Ë»ç, ½ÅÀå±â´É°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • multiple excitation
    ¹Ýº¹ÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple fission
    ¹µºÐ¿­, ´Ù¼öºÐ¿­
  • multiple fracture
    ´Ù¹ß°ñÀý
  • multiple sclerotic gait
    ´Ù¹ß°æÈ­Áõ°ÉÀ½
  • multiple infection
    ¿©·¯¹ø°¨¿°
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ
  • multiple field irradiation
    ´ÙÁ¶»ç¿µ¿ªÁ¶»ç
  • multiple keratoacanthoma
    ´Ù¹ß°¢Áú°¡½Ã¼¼Æ÷Á¾
  • multiple labor
    ´Ù»ê, ´Ùźи¸
  • multiple
    ´Ù¹ß-, ¿©·¯-, ¹µ-, ´Ù-
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple myositis
    ´Ù¹ß±ÙÀ°¿°
  • multiple neurofibromatosis
    ´Ù¹ß½Å°æ¼¶À¯Á¾Áõ
  • multiple neuroma
    ´Ù¹ß½Å°æÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Chopras test
    ¼îÇÁ¶ó°Ë»ç.
  • Congo red test
    Äá°íÀû½ÃÇè.»ýÈ­Äá°í·¹µå½ÃÇè.
  • Continuous Performance Test
    Áö¼Ó¼öÇà °Ë»ç
  • Coombs consumption test
    Äñ½º¼Ò¸ð°Ë»ç
  • Cosyntropin stimulation test
    ÄÚ½ÅÆ®·ÎÇÉ ÀڱؽÃÇè
  • Cuboni s test
    Äíº¸´Ï½ÃÇè.
  • Cytronbergs test
    ½ÃÆ®·Ðº£¸£Å©½ÃÇè.
  • DAT =>direct antiglobulin test
    Á÷Á¢ Çױ۷κҸ°½ÃÇè
  • DDST=Denver developmental screening test
    µ§¹ö¹ß´ÞÁ¶»ç°Ë»ç
  • DNase test
    DNA ºÐÇØÈ¿¼Ò½ÃÇè
  • DST=dexamethasone supression test
    µ¦»ç¸ÞŸ¼Õ ¾ïÁ¦°Ë»ç
  • Dehydration test
    Å»¼ö°Ë»ç
  • Denver Developmental Screening Test
    µ§¹ö¹ß´ÞÁ¶»ç°Ë»ç(Û¡Ó¹ðàÞÛËþÞÛ)
  • Denver developmental screening test
    µ§¹ö¹ßÀ°¼±º°¹ý.
  • Dick test
    µñÅ©½ÃÇè
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • multiple abscess
    ´Ù¹ß¼º ³ó¾ç(ÒýÛ¡àõÒÛåË).
  • multiple abscess
    ´Ù¹ß¼º ³ó¾ç(ÒýÛ¡àõÒÛåË)
  • multiple abscess
    ´Ù¹ß¼º ³ó¾ç(´Ù¹ß¼º³ó¾ç).
  • multiple alleles
    º¹´ë¸³ÀÎÀÚ, ´Ù¹ß¼º ´ë¸³ÇüÁú(ÒýÛ¡àõÓßí¡û¡òõ).
  • multiple allelic mutation
    º¹´ë¸³ÇüÁúº¯ÀÌ(ÜÜÓßí¡û¡òõܨì¶).
  • multiple allelism
    º¹´ë¸³(¼º)(¡­Óßí¡àõ).
  • multiple allelism
    º¹´ë¸³(¼º)(¡­Óßí¡àõ).
  • multiple allelomorph
    º¹´ë¸³À¯ÀüÀÚ(¡­Óßí¡ë¶îîí­).
  • multiple allelomorphism
    º¹´ë¸³¼º(¡­Óßí¡àõ).
  • multiple amputation
    ´ÙºÎÀ§ Àý´Ü(ÒýÝ»êÈôîÓ¨).
  • multiple angiofibroma
    ´Ù¹ß¼º Ç÷°ü ¼¶À¯Á¾
  • multiple benign cystic epithelioma
    ´Ù¹ß¼º ¾ç¼º ³¶Á¾¼º »óÇÇÁ¾
  • multiple birth
    ´Ù»ê(Òýß§), ´ÙÅÂÃâ»ê(Òý÷Ãõóß§).
  • multiple bond
    ´ÙÁß°áÇÕ(ÒýñìÌ¿ùê).
  • multiple budding
    ´Ù¼öÃâ¾Æ(Òýâ¦õóä´).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • immunoprecipitation test
    ¸é¿ªÄ§Àü ½ÃÇè(Øóæ¹öØîþãËúÐ)
  • indirect complement fixation test
    °£Á¢º¸Ã¼°íÁ¤½ÃÇè(ÊàïÈÜÍô÷ͳïÒãËúÐ)
  • indirect Coomb's test
    °£Á¢(ÊàïÈ) Äñ½ÃÇè(ãËúÐ)
  • insulin stimulating test
    Àν¶¸° ÀڱؽÃÇè(í©Ð½ãËúÐ)
  • insulin tolerance test
    Àν¶¸° ³»¼º½ÃÇè(Ò±àõãËúÐ)
  • interfacial test
    °è¸é°Ë»ç(Í£ØüËþÞÛ)
  • ketostix test
    ÄÉÅ佺ƽ°Ë»ç(ËþÞÛ)
  • lactose tolerance test
    "¶ôÅ佺 ºÎÇϰ˻ç(ݶùÃËþÞÛ), ¶ôÅ佺³»¼º°Ë»ç(Ò±àõËþÞÛ)"
  • liver function test
    °£±â´É °Ë»ç(ÊÜÐüÒöËþÞÛ)
  • load test
    ºÎÇϰ˻ç(ݶùÃËþÞÛ)
  • Luria-Delbrueck fluctuation test
    ·ç¸®¾Æ-µ¨ºê¸¯ ¿äµ¿½ÃÇè(èôÔÑãËúÐ)
  • metyrapone test
    ¸ÞƼ¶óÆù°Ë»ç(ËþÞÛ)
  • Molisch test
    ¸ô¸®½¬ ½ÃÇè(ãËúÐ)
  • Morner's test
    ¸ð³Ê ½ÃÇè(ãËúÐ)
  • murexide test
    ¹Â·¡½Ãµå°Ë»ç(ËþÞÛ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • treadmill exercise test
    ´äÂ÷¿îµ¿°Ë»ç
  • vestibular function test
    ÀüÁ¤±â´É°Ë»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ST esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor...
MEN Multiple Endocrine Neoplasia
  ; AD Trait
  1. MEN Type I(= Wermer Syndro...
MCS malignant carcinoid syndrome; managed care system; massage of the carotid sinus; mesocaval shunt; me...
PS test Pancreozymin-Secretion test
  = combined secretin-CCK test
AAT Aachen Aphasia Test; academic aptitude test; alanine aminotransferase; alkylating agent therapy; alp...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
PRID Progesterone Releasing Intravaginal Device
RVAD Right ventricular assist device
SQUID SUper Conducting Quantum Interference Device
SPMD semipermeable membrane device
VAD vascular access device
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • multiple osteoma
    ´Ù¹ß¼º °ñÁ¾
  • multiple papilloma
    ´Ù¹ß¼º À¯µÎÁ¾
  • multiple petechia
    ´Ù¹ß¼º Á¡»ó ÃâÇ÷
  • multiple photoreceptor
    ´Ù¹ß¼º ±¤ ¼ö¿ëü, ´Ù¹ß¼º ±¤ ¼ö¿ë±â
  • multiple projection
    ´Ù¹ß¼º Á¶»ç
  • multiple pulmonary emboli
    ´Ù¹ß¼º Æó »öÀü
  • multiple region
    ´Ù¹ß¼º ºÎÀ§
  • multiple rough gravellike sound
    ´Ù¹ß¼ºÀÇ °ÅÄ£ ÀÚ°¥ °¡´Â ¼Ò¸®
  • multiple seborrheic keratoses
    ´Ù¹ß Áö·ç¼º °¢È­Áõ
  • multiple sinus fracture
    ´Ù¹ß¼º ºÎºñµ¿ °ñÀý
  • multiple somatic receptor
    ´Ù¹ß¼º ü ¼ö¿ëü, ´Ù¹ß¼º ü ¼ö¿ë±â
  • multiple spike
    ´Ù¹ß¼º ½ºÆÄÀÌÅ©
  • multiple surgical procedure
    ´Ù¹ß¼º ¿Ü°úÀû Ä¡·á
  • multiple vascular tumor
    ´Ù¹ß¼º Ç÷°ü Á¾¾ç
  • multiple wart
    ´Ù¹ß¼º »ç¸¶±Í
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
multiple epiphysial dysplasia A dominantly inherited abnormality of epiphyses characterised by difficulty in walking, pain and stiffness of joints, stubby fingers, and often dwarfism of short-limb type; on X-ray examination, the epiphyses are mottled and irregular; ossification centres are late in appearance and may be multiple, but the vertebrae are normal. There is also an autosomal recessive form .
Synonym: dysplasia epiphysialis multiplex.
(05 Mar 2000)
multiple exostosis A disturbance of enchondral bone growth in which multiple, generally benign osteochondromas of long bones appear during childhood, commonly with shortening of the radius and fibula; the ill-effects are usually mechanical but malignant change is rare; autosomal dominant inheritance.
Synonym: diaphysial aclasis, hereditary deforming chondrodystrophy, multiple exostosis, osteochondromatosis.
(05 Mar 2000)
multiple fission Division of the nucleus, simultaneously or successively, into a number of daughter nuclei, followed by division of the cell body into an equal number of parts, each containing a nucleus.
(05 Mar 2000)
multiple fracture Fracture at two or more places in a bone.
See: segmental fracture.
Fracture of several bones occurring simultaneously.
(05 Mar 2000)
multiple gestation <radiology> Incidence: 1% of all births, twins in 1:85; triplets in 1:85x85; etc, uterus large for dates, may have elevated hCG, hPL, and aFP, at risk for IUGR: monochorionic-monoamniotic more than , monochorionic-diamniotic more than , dichorionic-diamniotic findings: 2 placentas indicate dichorionic-diamniotic, 1 placenta indicates monochorionic pregnancy or dichorionic pregnancy with fused placenta, separating membranes confirms diamniotic pregnancy
(12 Dec 1998)
multiple glandular deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple hamartoma syndrome Hypertrichosis and gingival fibromatosis from infancy, accompanied by postpubertal fibroadenomatous breast enlargement; papules of the face are characteristic of multiple trichilemmomas.
Synonym: multiple hamartoma syndrome.
(05 Mar 2000)
multiple idiopathic haemorrhagic sarcoma <oncology, tumour> A type of vascular cancer characterised by soft purple nodules that usually develop first on the feet and then slowly spread across the skin.This cancer is most often found in people with compromised immune systems, such as AIDS patients.
(09 Oct 1997)
multiple infection <epidemiology> An infection in which an individual is infected by parasites of more than one species.
(05 Dec 1998)
multiple intestinal polyposis Begins usually in late childhood; polyps increase in numbers, causing symptoms of chronic colitis, and carcinoma of the colon almost invariably develops in untreated cases; autosomal dominant inheritance. In the Gardner syndrome there are extracolonic changes (desmoid tumours, etc.).
Synonym: polyposis coli.
Hamartomatous polyposis of the small or large intestine, Peutz-Jeghers syndrome with melanin spots on the lips, less common, miscellaneous, rare, and doubtful occurrences.
Synonym: familial intestinal polyposis.
(05 Mar 2000)
multiple lentigines syndrome <syndrome> An autosomal dominant inherited disorder characterised by freckle-like spots (lentigines) on the trunk. Other findings may include wide set eyes, sternum abnormalities, prominent ears, deafness, cafe-au-lait spots, pulmonary stenosis, cryptorchidism, delayed puberty or hypogonadism. There is no treatment available only underlying management of each problem.
Inheritance: autosomal dominant.
(27 Sep 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • blood test
    Ç÷¾×°Ë»ç
  • breath test
    ÁÖ±â°Ë»ç
  • captive test (firing)
    (¹Ì»çÀÏ.·ÎÄÏ ¿£ÁøµîÀÇ)Áö»ó ºÐ»ç ½ÃÇè
  • cartoon test
    ¾àÈ­ Å×½ºÆ®
  • completion test
    ¿Ï¼ºÇü Å×½ºÆ®
  • doping test
    ±ÝÁö ¾à¹° °Ë»ç
  • doublebline test
    ÀÌÁß¸Í °Ë»ç¹ý(½Å¾à È¿°úÀÇ °Ë»ç¹ý)
  • driving test
    ¿îÀü ¸éÇã ½ÃÇè
  • drop test
    ³«ÇÏ ½ÃÇè(Å×½ºÆ®)
  • fatigue test
    ÇÇ·Î ½ÃÇè
  • film test
    ¿µÈ­ ¹è¿ì Áö¸ÁÀÚÀÇ Ä«¸Þ¶ó Å×½ºÆ®
  • herd test
    ¼Ò¶¼ÀÇ °Ë»ç(ƯÁ¤ Á¥¼Ò¶¼ÀÇ À¯Áö¹æ ÇÔÀ¯À² °Ë»ç)
  • inkblot test
    RORSCHACH TEST
  • intelligence test
    ±â´É°Ë»ç
  • intradermal test
    (ÀÇ)Çdz»(¸é¿ª)Å×½ºÆ®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á